Hidden danger: study probes blood clot risk in cancer patients with COVID-19
NCT ID NCT04616846
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study investigates how often cancer patients with COVID-19 develop dangerous blood clots (venous thromboembolism). Researchers will screen participants using ultrasound and blood tests to detect clots, whether or not they cause symptoms. The goal is to understand the true rate of clotting in this vulnerable group and help guide future prevention and treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify which cancer patients with COVID-19 are at highest risk for dangerous blood clots, leading to better screening and prevention guidelines.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test any new therapy. The findings may not apply to all cancer patients or all COVID-19 variants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHPG
Monaco, 98000, Monaco
-
CHU Nice
Nice, Alpes-Maritimes, 06000, France
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre Azuréen de Cancérologie
Mougins, Alpes-Maritimes, 06250, France
-
Clinique Saint-Georges
Nice, Alpes-Maritimes, 06105, France
-
Clinique Saint-Jean
Cagnes-sur-Mer, Alpes-Maritimes, 06800, France